Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8611165 | 0.81 | TSHR (0.48) | KMT2ANISCHL3MBTL1LMNAALDH1A1 | |
| SCHEMBL3244705 | 0.79 | — | — | |
| SCHEMBL9281903 | 0.78 | GABRA1 (0.39) | GABRA1GABRB2KMT2AMEN1P2RX3 | |
| SCHEMBL16335930 | 0.77 | GABRA1 (0.43) | GABRA1GABRB2CYP1A2CYP3A4LMNA | |
| SCHEMBL6571065 | 0.77 | CA1 (0.38) | KMT2AADRA2BLMNAALDH1A1TSHR | |
| SCHEMBL3635472 | 0.75 | ALDH1A1 (0.49) | KMT2AMEN1CYP1A2NISCHCYP2C19 | |
| SCHEMBL4575432 | 0.75 | P2RX3 (0.58) | GABRA1GABRB2KMT2AMEN1P2RX3 | |
| SCHEMBL31257131 | 0.75 | CA1 (0.60) | GABRA1GABRB2KMT2AMEN1P2RX3 | |
| SCHEMBL141647 | 0.75 | CA1 (0.60) | GABRA1GABRB2KMT2AMEN1P2RX3 | |
| SCHEMBL29959656 | 0.75 | P2RX3 (0.58) | GABRA1GABRB2KMT2AMEN1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5234930-A | Treating psychological, cardiovascular, urogenital and respiratory disorders; diabetes, asthmas, sudden infant death syndrome | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-10 | — | — | US | claimed |
| EP-2160396-B1 | THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES INC (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-2476689-B1 | Thiocarbon-protecting groups for RNA synthesis | AGILENT TECHNOLOGIES INC (US) | 2015-10-21 | — | — | EP | disclosed |
| EP-1556389-B9 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-09-09 | — | — | EP | disclosed |
| US-9067961-B2 | Thiocarbon-protecting groups for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| EP-1556389-B3 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-04-01 | — | — | EP | disclosed |
| US-20120238737-A1 | THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| EP-2476689-A1 | Thiocarbon-protecting groups for RNA synthesis | Agilent Technologies, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-8202983-B2 | Thiocarbon-protecting groups for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| EP-1663245-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-6060586-A | Ureins derived from alpha, omega-diamono acids and process for their preparation | SOLVAY (SOCIETE ANONYME) (BE) | 2000-05-09 | — | — | US | disclosed |
| EP-0925299-A1 | PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-06-30 | — | — | EP | disclosed |
| US-5773530-A | USEFUL AS PSYCHOSTIMULANTS, ANTIHYPERTENSIVE AGENTS AND REMEDIES FOR RENAL FAILURE, DIURETICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-30 | — | — | US | disclosed |
| WO-1998003507-A1 | PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-29 | — | — | WO | disclosed |
| WO-1997041128-A1 | 3-PYRAZOLIOMETHYLCEPHEM COMPOUNDS AS ANTIMICROBIAL AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-11-06 | — | — | WO | disclosed |
| EP-0737193-A1 | PYRAZOLOPYRIDINE ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-16 | — | — | EP | disclosed |
| US-5506362-A | Process for the preparation of an α-amino acid amide | SOLVAY (SOCIETE ANONYME) (BE) | 1996-04-09 | — | — | US | disclosed |
| WO-1995018128-A1 | PYRAZOLOPYRIDINE ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-06 | — | — | WO | disclosed |
| US-5234930-A | Treating psychological, cardiovascular, urogenital and respiratory disorders; diabetes, asthmas, sudden infant death syndrome | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-10 | — | — | US | disclosed |
| EP-0516941-A1 | Pyrazolopyridine compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238737-A1 | THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS | NSUN3, NSUN2, TRDMT1 | GABRA1 4599/4885GABRB2 3817/4885KMT2A 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.